{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:05:53Z","timestamp":1779246353787,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16004-3","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:05:23Z","timestamp":1776053123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Off-label drug use in oncology practice: a nationwide cross-sectional survey among Turkish medical oncologists"],"prefix":"10.1186","volume":"26","author":[{"given":"Merih","family":"Yal\u00e7iner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efe Cem","family":"Erdat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Akbulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"16004_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jcpt.12507","volume":"42","author":"MM Saiyed","year":"2017","unstructured":"Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42:251\u20138. https:\/\/doi.org\/10.1111\/jcpt.12507.","journal-title":"J Clin Pharm Ther"},{"key":"16004_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/030089160909500601","volume":"95","author":"F Roila","year":"2009","unstructured":"Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, et al. Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. Tumori J. 2009;95:647\u201351. https:\/\/doi.org\/10.1177\/030089160909500601.","journal-title":"Tumori J"},{"key":"16004_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00228-011-1173-6","volume":"68","author":"R Lerose","year":"2012","unstructured":"Lerose R, Musto P, Aieta M, Papa C, Tartarone A. Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience. Eur J Clin Pharmacol. 2012;68:505\u201312. https:\/\/doi.org\/10.1007\/s00228-011-1173-6.","journal-title":"Eur J Clin Pharmacol"},{"key":"16004_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/0973-1482.80455","volume":"7","author":"V Gota","year":"2011","unstructured":"Gota V, Patial P. Off-label use of anti-cancer drugs in India: To be or not to be! J Cancer Res Ther. 2011;7:35\u20139. https:\/\/doi.org\/10.4103\/0973-1482.80455.","journal-title":"J Cancer Res Ther"},{"key":"16004_CR5","doi-asserted-by":"publisher","first-page":"E210380","DOI":"10.1001\/jamanetworkopen.2021.0380","volume":"4","author":"AK Herbrand","year":"2021","unstructured":"Herbrand AK, Schmitt AM, Briel M, Ewald H, Goldkuhle M, Diem S, et al. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open. 2021;4:E210380. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0380.","journal-title":"JAMA Netw Open"},{"key":"16004_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00228-014-1662-5","volume":"70","author":"M Joerger","year":"2014","unstructured":"Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, et al. Off-label use of anticancer drugs in eastern Switzerland: A population-based prospective cohort study. Eur J Clin Pharmacol. 2014;70:719\u201325. https:\/\/doi.org\/10.1007\/s00228-014-1662-5.","journal-title":"Eur J Clin Pharmacol"},{"key":"16004_CR7","doi-asserted-by":"publisher","unstructured":"Zarkavelis G, Amylidi AL, Verbaanderd C, Cherny NI, Metaxas Y, de Vries EGE, et al. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open. 2023;8. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100604.","DOI":"10.1016\/j.esmoop.2022.100604"},{"key":"16004_CR8","doi-asserted-by":"publisher","unstructured":"Liu R, Wang L, Rizzo S, Garmhausen MR, Pal N, Waliany S, et al. Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients. Cell Rep Med. 2024;5. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101444.","DOI":"10.1016\/j.xcrm.2024.101444"},{"key":"16004_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S1470-2045(08)70280-8","volume":"9","author":"D Lev\u00eaque","year":"2008","unstructured":"Lev\u00eaque D. Off-label use of anticancer drugs. Lancet Oncol. 2008;9:1102\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(08)70280-8.","journal-title":"Lancet Oncol"},{"key":"16004_CR10","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1200\/JOP.2014.001354","volume":"11","author":"JA Kalis","year":"2015","unstructured":"Kalis JA, Pence SJ, Mancini RS, Zuckerman DS, Ineck JR. Prevalence of Off-Label Use of Oral Oncolytics at a Community Cancer Center. J Oncol Pract. 2015;11:e139\u201343. https:\/\/doi.org\/10.1200\/JOP.2014.001354.","journal-title":"J Oncol Pract"},{"key":"16004_CR11","doi-asserted-by":"publisher","unstructured":"Schmitt AM, Walter M, Herbrand AK, J\u00f6rger M, Moffa G, Novak U, et al. Characteristics and survival of patients with cancer with intended off-label use - A cohort study. BMJ Open. 2022;12. https:\/\/doi.org\/10.1136\/bmjopen-2021-060453.","DOI":"10.1136\/bmjopen-2021-060453"},{"key":"16004_CR12","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1200\/JCO.2008.18.1420","volume":"26","author":"J Peppercorn","year":"2008","unstructured":"Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008;26:5994\u20136000. https:\/\/doi.org\/10.1200\/JCO.2008.18.1420.","journal-title":"J Clin Oncol"},{"key":"16004_CR13","doi-asserted-by":"crossref","unstructured":"Burstein HJ. Off-Label Use of Oncology Drugs: Too Much, Too Little, or Just Right? 2013.","DOI":"10.6004\/jnccn.2013.0066"},{"key":"16004_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.2011.38.5567","volume":"30","author":"DG Pfister","year":"2012","unstructured":"Pfister DG. Off-Label Use of Oncology Drugs: The Need for More Data and Then Some. J Clin Oncol. 2012;30:584\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.38.5567.","journal-title":"J Clin Oncol"},{"key":"16004_CR15","unstructured":"Real Decreto 1015\/. 2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales. Bolet\u00edn Oficial del Estado. 2009;174:60904\u201313."},{"key":"16004_CR16","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1002\/hec.3537","volume":"27","author":"F Smieliauskas","year":"2018","unstructured":"Smieliauskas F, Sharma H, Hurley C, de Souza JA, Shih YCT. State insurance mandates and off-label use of chemotherapy. Health Econ (United Kingdom). 2018;27:e55\u201370. https:\/\/doi.org\/10.1002\/hec.3537.","journal-title":"Health Econ (United Kingdom)"},{"key":"16004_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2298\/MPNS1502035G","volume":"68","author":"S Golo\u010dorbin Kon","year":"2015","unstructured":"Golo\u010dorbin Kon S, Ilikovi\u0107 I, Mikov M. Reasons for and frequency of off-label drug use. Med Pregl. 2015;68:35\u201340. https:\/\/doi.org\/10.2298\/MPNS1502035G.","journal-title":"Med Pregl"},{"key":"16004_CR18","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1200\/OP.20.00131","volume":"17","author":"S Bun","year":"2021","unstructured":"Bun S, Yonemori K, Sunadoi H, Nishigaki R, Noguchi E, Okusaka T, et al. Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. JCO Oncol Pract. 2021;17:e416\u201325. https:\/\/doi.org\/10.1200\/OP.20.00131.","journal-title":"JCO Oncol Pract"},{"key":"16004_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.32471\/exp-oncology.2312-8852.vol-43-no-1.15583","volume":"43","author":"SM Drogovoz","year":"2021","unstructured":"Drogovoz SM, Starikov VI, Ivantsyk LB, Shchokina KG. Experience and prospects for the use of off-label drugs in oncology. Exp Oncol. 2021;43:1\u20135. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-43-no-1.15583.","journal-title":"Exp Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16004-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:14:17Z","timestamp":1779243257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16004-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16004"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16004-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ankara University Ethics Committee; Approval number: 2025000917-1; Date: 26.11.2025. Participation was voluntary and anonymous; electronic completion of the survey constituted implied informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"648"}}